Human papillomavirus type 16 E6/E7-specific cytotoxic T lymphocytes for adoptive immunotherapy of HPV-associated malignancies

Journal of Immunotherapy

Volumn 36, Issue 1, 2013, Pages 66-76

  Ramos, Carlos A ^a,b   Narala, Neeharika ^a   Vyas, Gayatri M ^a   Leen, Ann M ^a,b   Gerdemann, Ulrike ^a   Sturgis, Erich M ^b   Anderson, Matthew L ^b,c   Savoldo, Barbara ^a,b   Heslop, Helen E ^a,b   Brenner, Malcolm K ^a,b   Rooney, Cliona M ^a,b,c  

^a TEXAS CHILDREN S HOSPITAL   (United States)

^b BAYLOR COLLEGE OF MEDICINE   (United States)

^c UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

Author keywords

adoptive T cell therapy; cervical cancer; E6; E7; head and neck cancer; HPV; HPV16; immunotherapy

Indexed keywords

AMINO ACID; CYTOKINE; GAMMA INTERFERON; INTERLEUKIN 12; INTERLEUKIN 15; INTERLEUKIN 6; INTERLEUKIN 7; PROTEIN E6; PROTEIN E7; VIRUS ANTIGEN;

ADOPTIVE IMMUNOTHERAPY; ANTIGEN EXPRESSION; ANTIGEN RECOGNITION; ARTICLE; CLONAL ANERGY; CYTOKINE RELEASE; CYTOTOXIC T LYMPHOCYTE; CYTOTOXICITY; DENDRITIC CELL; EX VIVO STUDY; GOOD MANUFACTURING PRACTICE; HUMAN; HUMAN CELL; HUMAN PAPILLOMAVIRUS TYPE 16; MAJOR CLINICAL STUDY; MEMORY T LYMPHOCYTE; NUCLEOTIDE SEQUENCE; OROPHARYNX CANCER; POLYCLONAL ACTIVATION; PRIORITY JOURNAL; T LYMPHOCYTE ACTIVATION; T LYMPHOCYTE SUBPOPULATION; TH1 CELL; UTERINE CERVIX CANCER;

FEMALE; HUMAN PAPILLOMAVIRUS 16; HUMANS; IMMUNOTHERAPY, ADOPTIVE; ONCOGENE PROTEINS, VIRAL; OROPHARYNGEAL NEOPLASMS; PAPILLOMAVIRUS E7 PROTEINS; PAPILLOMAVIRUS INFECTIONS; REPRESSOR PROTEINS; T-LYMPHOCYTES, CYTOTOXIC; UTERINE CERVICAL NEOPLASMS;

EID: 84871918505     PISSN: 15249557     EISSN: 15374513     Source Type: Journal    
DOI: 10.1097/CJI.0b013e318279652e     Document Type: Article

References (50)

1. D'Souza G, Kreimer AR, Viscidi R, et al. Case-control studyof human papillomavirus and oropharyngeal cancer. N Engl JMed. 2007;356:1944-1956 (Pubitemid 46740304)
2. Furniss CS, McClean MD, Smith JF, et al. Human papillomavirus16 and head and neck squamous cell carcinoma. IntJ Cancer. 2007;120:2386-2392 (Pubitemid 46642125)
3. Gillison ML, Koch WM, Capone RB, et al. Evidence for acausal association between human papillomavirus and a subsetof head and neck cancers. J Natl Cancer Inst. 2000;92:709-720 (Pubitemid 30365531)
4. Psyrri A, DiMaio D. Human papillomavirus in cervical andhead-and-neck cancer. Nat Clin Pract Oncol. 2008;5:24-31 (Pubitemid 351512426)
5. Syrjanen S. Human papillomaviruses in head and neckcarcinomas. N Engl J Med. 2007;356:1993-1995
6. zur Hausen H. Papillomaviruses and cancer: from basic studiesto clinical application. Nat Rev Cancer. 2002;2:342-350 (Pubitemid 37328947)
7. Hoots BE, Palefsky JM, Pimenta JM, et al. Humanpapillomavirus type distribution in anal cancer and analintraepithelial lesions. Int J Cancer. 2009;124:2375-2383
8. Miralles-Guri C, Bruni L, Cubilla A, et al. HPV prevalenceand type distribution in penile carcinoma. J Clin Pathol.2009;62:870-878
9. Jemal A, Siegel R, Ward E, et al. Cancer statistics, 2009. CACancer J Clin. 2009;59:225-249
10. Forastiere AA, Ang KK, Brizel D, et al. Head and neckcancers. J Natl Compr Cancer Netw. 2008;6:646-695
11. Greer BE, Koh WJ, Abu-Rustum N, et al. Cervical cancer.J Natl Compr Cancer Netw. 2008;6:14-36
12. Doorbar J. Papillomavirus life cycle organization and biomarkerselection. Dis Markers. 2007;23:297-313 (Pubitemid 47015790)
13. Stanley MA, Pett MR, Coleman N. HPV: from infection tocancer. Biochem Soc Trans. 2007;35:1456-1460
14. Kenter GG, Welters MJ, Valentijn AR, et al. Phase Iimmunotherapeutic trial with long peptides spanning the E6and E7 sequences of high-risk human papillomavirus 16 in endstagecervical cancer patients shows low toxicity and robustimmunogenicity. Clin Cancer Res. 2008;14:169-177 (Pubitemid 351377993)
15. Welters MJ, Kenter GG, Piersma SJ, et al. Induction of tumorspecificCD4+ and CD8+ T-cell immunity in cervical cancerpatients by a human papillomavirus type 16 E6 and E7 longpeptides vaccine. Clin Cancer Res. 2008;14:178-187 (Pubitemid 351377994)
16. Teague RM, Sather BD, Sacks JA, et al. Interleukin-15 rescuestolerant CD8+ T cells for use in adoptive immunotherapy ofestablished tumors. Nat Med. 2006;12:335-341 (Pubitemid 43355083)
17. Korn T, Mitsdoerffer M, Croxford AL, et al. IL-6 controlsTh17 immunity in vivo by inhibiting the conversion ofconventional T cells into Foxp3+ regulatory T cells. ProcNatl Acad Sci USA. 2008;105:18460-18465
18. Leen AM, Christin A, Myers GD, et al. Cytotoxic Tlymphocyte therapy with donor T cells prevents and treatsadenovirus and Epstein-Barr virus infections after haploidenticaland matched unrelated stem cell transplantation. Blood.2009;114:4283-4292
19. Dotti G, Savoldo B, Yotnda P, et al. Transgenic expression ofCD40 ligand produces an in vivo antitumor immune responseagainst both CD40(+) and CD40(-) plasmacytoma cells.Blood. 2002;100:200-207 (Pubitemid 35177448)
20. Gerdemann U, Christin AS, Vera JF, et al. Nucleofection ofDCs to generate multivirus-specific T cells for prevention ortreatment of viral infections in the immunocompromised host.Mol Ther. 2009;17:1616-1625
21. von Bergwelt-Baildon MS, Vonderheide RH, Maecker B, et al.Human primary and memory cytotoxic T lymphocyteresponses are efficiently induced by means of CD40-activatedB cells as antigen-presenting cells: potential for clinicalapplication. Blood. 2002;99:3319-3325 (Pubitemid 34525313)
22. Wiesner M, Zentz C, Mayr C, et al. Conditional immortalizationof human B cells by CD40 ligation. PLoS One.2008;3:e1464
23. Thomas KJ, Smith KL, Youde SJ, et al. HPV16 E6 29-38-specific T cells kill cervical carcinoma cells despite partial evasionof T-cell effector function. Int J Cancer. 2008;122:2791-2799 (Pubitemid 351631382)
24. Bourgault Villada I, Moyal Barracco M, Berville S, et al.Human papillomavirus 16-specific T cell responses in classicHPV-related vulvar intra-epithelial neoplasia. Determinationof strongly immunogenic regions from E6 and E7 proteins.Clin Exp Immunol. 2010;159:45-56
25. de Jong A, van der Hulst JM, Kenter GG, et al. Rapidenrichment of human papillomavirus (HPV)-specific polyclonalT cell populations for adoptive immunotherapy of cervicalcancer. Int J Cancer. 2005;114:274-282 (Pubitemid 40194297)
26. Wang X, Moscicki AB, Tsang L, et al. Memory T cells specificfor novel human papillomavirus type 16 (HPV16) E6 epitopesin women whose HPV16 infection has become undetectable.Clin Vaccine Immunol. 2008;15:937-945 (Pubitemid 351967007)
27. Nilges K, Hohn H, Pilch H, et al. Human papillomavirus type16 E7 peptide-directed CD8+ T cells from patients withcervical cancer are cross-reactive with the coronavirus NS2protein. J Virol. 2003;77:5464-5474 (Pubitemid 36460959)
28. Riemer AB, Keskin DB, Zhang G, et al. A conserved E7-derived cytotoxic T lymphocyte epitope expressed on humanpapillomavirus 16-transformed HLA-A2+ epithelial cancers.J Biol Chem. 2010;285:29608-29622
29. Youde SJ, Dunbar PR, Evans EM, et al. Use of fluorogenichistocompatibility leukocyte antigen-A 0201/HPV 16 E7 peptidecomplexes to isolate rare human cytotoxic T- lymphocyterecognizingendogenous human papillomavirus antigens.Cancer Res. 2000;60:365-371 (Pubitemid 30070764)
30. Delgado FG, Martinez E, Cespedes MA, et al. Increase ofhuman papillomavirus-16 E7-specific T helper type 1 responsein peripheral blood of cervical cancer patients after radiotherapy.Immunology. 2009;126:523-534
31. Kenter GG, Welters MJ, Valentijn AR, et al. Vaccinationagainst HPV-16 oncoproteins for vulvar intraepithelial neoplasia.N Engl J Med. 2009;361:1838-1847
32. van der Burg SH, de Jong A, Welters MJ, et al. The status ofHPV16-specific T-cell reactivity in health and disease as a guideto HPV vaccine development. Virus Res. 2002;89:275-284 (Pubitemid 35351546)
33. Gottschalk S, Edwards OL, Sili U, et al. Generating CTLsagainst the subdominant Epstein-Barr virus LMP1 antigen forthe adoptive immunotherapy of EBV-associated malignancies.Blood. 2003;101:1905-1912 (Pubitemid 36237592)
34. Bollard CM, Gottschalk S, Leen AM, et al. Completeresponses of relapsed lymphoma following genetic modificationof tumor-antigen presenting cells and T-lymphocytetransfer. Blood. 2007;110:2838-2845 (Pubitemid 350006936)
35. Vella A, Teague TK, Ihle J, et al. Interleukin 4 (IL-4) or IL-7prevents the death of resting T cells: stat6 is probably notrequired for the effect of IL-4. J Exp Med. 1997;186:325-330 (Pubitemid 27328033)
36. Indrova M, Bieblova J, Rossowska J, et al. HPV 16-associatedtumours: IL-12 can repair the absence of cytotoxic andproliferative responses of tumour infiltrating cells after chemotherapy.Int J Oncol. 2009;34:173-179
37. Hombach A, Kohler H, Rappl G, et al. Human CD4+ T cellslyse target cells via granzyme/perforin upon circumvention of MHC class II restriction by an antibody-like immunoreceptor.J Immunol. 2006;177:5668-5675 (Pubitemid 44527643)
38. Heslop HE, Slobod KS, Pule MA, et al. Long-term outcome ofEBV-specific T-cell infusions to prevent or treat EBV-relatedlymphoproliferative disease in transplant recipients. Blood.2010;115:925-935.
39. Cheadle EJ, Hawkins RE, Batha H, et al. Eradication ofestablished B-cell lymphoma by CD19-specific murine T cellsis dependent on host lymphopenic environment and canbe mediated by CD4+ and CD8+ T cells. J Immunother.2009;32: 207-218
40. Bollard CM, Rossig C, Calonge MJ, et al. Adapting atransforming growth factor beta-related tumor protectionstrategy to enhance antitumor immunity. Blood. 2002;99:3179-3187 (Pubitemid 34525296)
41. Giannini SL, Al-Saleh W, Piron H, et al. Cytokine expressionin squamous intraepithelial lesions of the uterine cervix:implications for the generation of local immunosuppression.Clin Exp Immunol. 1998;113:183-189 (Pubitemid 28352835)
42. van der Burg SH, Piersma SJ, de Jong A, et al. Association ofcervical cancer with the presence of CD4+ regulatory T cellsspecific for human papillomavirus antigens. Proc Natl Acad SciUSA. 2007;104:12087-12092 (Pubitemid 47185634)
43. Strauss L, Bergmann C, Whiteside TL. Functional andphenotypic characteristics of CD4+CD25highFoxp3+ Tregclones obtained from peripheral blood of patients with cancer.Int J Cancer. 2007;121:2473-2483 (Pubitemid 350022417)
44. Foster AE, Dotti G, Lu A, et al. Antitumor activity of EBVspecificT lymphocytes transduced with a dominant negativeTGF-beta receptor. J Immunother. 2008;31:500-505
45. Dudley ME, Wunderlich JR, Robbins PF, et al. Cancerregression and autoimmunity in patients after clonal repopulationwith antitumor lymphocytes. Science. 2002;298:850-854 (Pubitemid 35231542)
46. Dudley ME,Wunderlich JR, Yang JC, et al. A phase I study ofnonmyeloablative chemotherapy and adoptive transfer ofautologous tumor antigen-specific T lymphocytes in patientswith metastatic melanoma. J Immunother. 2002;25:243-251 (Pubitemid 34533314)
47. Ahmadzadeh M, Rosenberg SA. IL-2 administration increasesCD4+ CD25(hi) Foxp3+ regulatory T cells in cancerpatients. Blood. 2006;107:2409-2414 (Pubitemid 43345561)
48. Ma A, Boone DL, Lodolce JP. The pleiotropic functions ofinterleukin 15: not so interleukin 2-like after all. J Exp Med.2000;191:753-756
49. Alpdogan O, Eng JM, Muriglan SJ, et al. Interleukin-15enhances immune reconstitution after allogeneic bone marrowtransplantation. Blood. 2005;105:865-873 (Pubitemid 40070777)
50. Strauss L, Bergmann C, Whiteside TL. IL-15 administration tohuman CD4+ T cells leads to expansion of CD4+CD25-cells but to a decrease of CD4+CD25highFoxp3+T cells viaapoptosis. J Immunol. 2007;178:S147